Skip to main content
    B

    Biohaven Ltd. (BHVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $13.82
    +0.00 (+0.00%)

    Market Cap: $2.09B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biohaven Ltd. (BHVN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Biohaven reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$738.82M, operating cash flow was -$609.44M and free cash flow was -$610.15M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$129.28M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $745.38M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2017
    Research and development$635.07M$795.87M$373.28M$437.07M$181.49M$98.46M$344.67M$0
    Operating income-$745.38M-$885.11M-$436.05M-$567.93M-$218.90M-$114.51M-$479.12MN/A
    Net income-$738.82M-$846.42M-$408.17M-$570.28M-$213.80M-$118.67M-$528.80MN/A
    EBITDA-$727.46M-$837.83M-$402.64MN/A-$216.30M-$114.43M-$479.12MN/A
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.84M$0$0$0$0
    Gross profit$0$0$0-$960.00K$0$0$0$1.92M$0$0$0-$948.00K
    Operating income-$126.42M-$124.90M-$130.43M-$142.73M-$169.38M-$211.70M-$221.56M-$189.93M-$178.17M-$333.77M-$183.24M-$153.71M
    Net income-$129.28M-$137.31M-$130.53M-$145.56M-$173.44M-$198.15M-$221.68M-$186.84M-$160.30M-$319.77M-$179.50M-$144.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $244.66M exceeded cash and equivalents by $14.70M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$451.45M$615.11M$513.21M$661.78M$142.06M$111.50M$344.26M$290.01M$146.89M
    Current assets$368.33M$538.47M$442.45M$586.97M$94.82M$89.76M$328.28M$272.34M$136.66M
    Cash and equivalents$229.96M$99.13M$248.40M$204.88M$76.06M$82.51M$316.73M$264.25M$131.47M
    Total liabilities$399.38M$191.67M$85.24M$123.01M$47.37M$34.72M$351.69M$139.09M$14.92M
    Short-term debt$5.76M$3.80M$3.31M$3.02M$439.00K$675.00KN/AN/AN/A
    Long-term debt$238.90M$0N/AN/A$626.72MN/AN/AN/AN/A
    Shareholder equity$52.07M$423.44M$427.98M$538.77M$34.69M$76.78M-$7.42M$150.92M$131.97M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$263.68M$370.74M$466.41M$451.45M$409.12M$550.41M$458.95M$615.11M$510.52M$582.64M$418.53M$513.21M
    Total liabilities$361.92M$358.52M$336.91M$399.38M$426.28M$415.83M$199.45M$191.67M$194.52M$198.90M$117.08M$85.24M
    Cash and equivalents$95.75M$238.03M$273.07M$229.96M$184.85M$165.80M$98.42M$99.13M$84.39M$239.15M$182.71M$248.40M
    Shareholder equity-$98.25M$12.22M$129.50M$52.07M-$17.16M$134.59M$259.50M$423.44M$316.01M$383.74M$301.45M$427.98M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$609.44M-$582.45M-$331.73M-$297.69M-$145.84M-$75.96M-$377.33M-$197.14M-$94.81M
    Capital expenditures$715.00K$4.05M$3.05M$6.07M$938.00K$1.10M$2.53M$4.17M$541.00K
    Free cash flow-$610.15M-$586.50M-$334.77M-$303.76M-$146.78M-$77.05M-$379.87M-$201.31M-$95.36M
    Share repurchases$1.70M$2.15M$800.00K$1.00M$0$0N/AN/AN/A
    Investing cash flow$300.56M-$244.97M$129.83M-$304.79M$944.00K-$2.70M-$3.78M-$10.54M-$7.04M
    Financing cash flow$439.12M$677.77M$211.91M$767.60M$138.45M$152.24M$434.59M$340.46M$209.76M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$106.85M-$85.10M-$149.92M-$130.66M-$145.72M-$167.94M-$165.12M-$170.74M-$141.28M-$167.80M-$102.64M-$114.88M
    Capital expenditures$180.00K$454.00K$0$8.00K$13.00K$233.00K$461.00K$49.00K$611.00K$2.95M$440.00K$470.00K
    Free cash flow-$107.03M-$85.55M-$149.92M-$130.67M-$145.73M-$168.17M-$165.59M-$170.79M-$141.89M-$170.75M-$103.08M-$115.35M
    Last 12 quarters

    Frequently Asked Questions About BHVN

    What is Biohaven's annual revenue?

    Biohaven reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Biohaven profitable?

    No. Biohaven reported net income of -$738.82M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does BHVN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$609.44M minus capital expenditures of $715.00K produced free cash flow of -$610.15M.

    How much debt does Biohaven have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $238.90M, short-term debt of $5.76M and cash and equivalents of $229.96M.